查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971316

他汀类药物市场－全球产业规模、份额、趋势、机会、预测：按类型、最终用户、地区和竞争格局划分，2021-2031年

Statin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Synthetic statin, Natural statin), By End-user (Hospitals & Clinics, Ambulatory Surgical Centers, others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球他汀类药物市场预计将从 2025 年的 29.2 亿美元成长到 2031 年的 34.6 亿美元，复合年增长率为 2.87%。

他汀类药物透过抑制HMG-CoA还原酶来降低低密度脂蛋白胆固醇水平，从而预防心血管事件。这一市场扩张的主要驱动力是全球心血管疾病发生率的上升以及老年人口不断增长，他们需要进行预防性血脂管理。例如，美国心臟协会（AHA）估计，到2024年，美国约有48.6%的成年人将患有某种形式的心血管疾病，凸显了医疗保健领域对有效胆固醇调节疗法的持续需求。

市场概览
预测期 2027-2031
市场规模：2025年 29.2亿美元
市场规模：2031年 34.6亿美元
复合年增长率：2026-2031年 2.87%
成长最快的细分市场 合成他汀类药物
最大的市场 北美洲

儘管市场需求强劲，但与他汀类药物使用相关的副作用报告，例如肌肉疼痛和血糖值升高，正在阻碍市场成长。这些不良反应往往导致患者依从性下降和治疗中断，对全球他汀类药物市场的持续扩张构成重大挑战。因此，由于耐受性问题导致的治疗中断风险仍然是该市场积极成长的主要障碍，而疾病的高发生率则支撑了市场的正面成长。

市场驱动因素

心血管疾病和血脂异常症的日益普遍是全球他汀类药物市场的主要驱动力，因为这需要更广泛的药物干预来管理患者的健康。高胆固醇症是缺血性心臟疾病和中风的重要危险因素，促使医疗保健提供者将降血脂药物作为基本的预防措施。美国疾病管制与预防中心 (CDC) 于 2024 年 11 月发布的第 515 号数据简报强调了这一趋势，该简报报告称，在 2021 年 8 月至 2023 年 8 月期间，约有 11.3% 的 20 岁及以上美国成年人的总胆固醇水平达到超过 240 mg/dL。这确保了需要治疗的患者数量持续成长，从而保障了製造商稳定的收入。

同时，社会快速老化正成为一个重要的人口因素，因为心血管疾病的风险会随着老龄化的增长而显着增加。老年人通常需要管理慢性疾病，并且是降胆固醇药物的最大消费族群。根据联合国人口基金（UNFPA）2024年6月发布的题为《老化》的报导，到2024年，全球65岁及以上人口的比例将达到10.3%，几乎是1974年以来的两倍。这种人群结构的变化与处方量的增加直接相关。英国国家医疗服务体系（NHS）商业服务的一份报告显示，Atorvastatin是2024年英格兰处方量最大的化学品，在2023/2024财年的处方量达到了6500万片。

市场挑战

全球他汀类药物市场成长的主要挑战是患者依从性低和治疗中断，尤其是由于肌肉疼痛和血糖值升高等副作用。当患者出现这些不良反应时，他们往往会停止用药或未能遵循处方治疗方案，这种趋势会扰乱製药业持续获利所必需的长期处方週期，从而直接导致市场规模萎缩。此外，对这些副作用的担忧也会造成心理障碍，阻碍患者开始治疗，导致合格的患者即使有控制血脂的临床需求，也会延迟或拒绝他汀类药物治疗。

这一障碍造成了潜在受益于治疗的患者群体与实际接受治疗的患者数量之间存在显着差距。根据欧洲心臟学会2024年的数据，约有21.8%的高风险或极高风险心血管风险患者未接受任何降血脂治疗。这项统计数据凸显了耐受性和依从性问题如何有效地阻碍了市场渗透，使该行业无法充分利用全球日益增长的心血管保护需求。

市场趋势

固定剂量组合药物製剂（FDC）的日益普及，特别是他汀类药物与ezetimibe的联合製剂，使得在不增加他汀类药物剂量的情况下也能有效降低血脂。这种策略在获得更佳临床疗效的同时，也能减轻高剂量单药治疗带来的副作用。 News-Medical.net 于 2025 年 3 月发表的Meta分析显示，与ezetimibe汀类药物单药治疗相比，依折麦布联合高剂量他汀类药物可显着降低全因死亡风险 19%。这促使製药公司优先研发此类双效製剂，以满足有效控制胆固醇的需求。

同时，心血管复方製剂的出现正在改变二级预防的格局，它将他汀类药物、降血压药和阿斯匹灵整合到单剂量製剂中。这一趋势可望透过简化复杂的日常用药流程和提高患者依从性，显着降低全球疾病负担。根据 tctmd.com 网站 2025 年 7 月发布的报告显示，到 2050 年，此类单药复方製剂的广泛应用可在全球范围内预防多达 2900 万人死亡。因此，製造商正在加速投资研发这些多机制产品，旨在从预防医学领域获得长期效益。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球他汀类药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（合成他汀类药物、天然他汀类药物）
    • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美他汀类药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲他汀类药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区他汀类药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲他汀类药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲他汀类药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球他汀类药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Abbott Laboratories Ltd.
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Biocon Ltd.
  • Concord Biotech Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 21811

The Global Statin Market is projected to expand from USD 2.92 Billion in 2025 to USD 3.46 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 2.87%. Statins are pharmaceutical agents that inhibit HMG-CoA reductase to lower low-density lipoprotein cholesterol levels and prevent cardiovascular events. This market expansion is largely driven by the increasing global burden of cardiovascular diseases and a growing geriatric population that requires preventative lipid management. For instance, the American Heart Association estimated in 2024 that approximately 48.6 percent of adults in the United States suffered from some form of cardiovascular disease, underscoring the persistent demand for effective cholesterol-regulating treatments within the healthcare sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.92 Billion
Market Size 2031USD 3.46 Billion
CAGR 2026-20312.87%
Fastest Growing SegmentSynthetic Statin
Largest MarketNorth America

Despite this strong demand, market progression faces obstacles due to documented side effects associated with statin use, such as muscle pain and elevated blood sugar levels. These adverse reactions often lead to patient non-adherence or the discontinuation of therapy, presenting a significant challenge to the sustained expansion of the global statin market. Consequently, the potential for treatment cessation due to intolerance remains a critical hurdle that counters the otherwise positive market trajectory fueled by disease prevalence.

Market Driver

The escalating prevalence of cardiovascular diseases and dyslipidemia serves as the primary catalyst propelling the Global Statin Market, as these conditions require extensive pharmacological intervention to manage patient health. High cholesterol levels act as a critical risk factor for ischemic heart disease and stroke, compelling healthcare providers to prescribe lipid-lowering agents as a fundamental preventive measure. This trend is highlighted by the Centers for Disease Control and Prevention in their November 2024 'NCHS Data Brief No. 515', which noted that approximately 11.3 percent of United States adults aged 20 and older had high total cholesterol levels of 240 mg/dL or more between August 2021 and August 2023, ensuring a continuous stream of patients requiring therapy and securing steady revenue for manufacturers.

Concurrently, the rapid expansion of the global geriatric population functions as a powerful demographic driver, given that susceptibility to cardiovascular ailments increases significantly with age. Older adults often require chronic disease management, making them the largest consumer segment for cholesterol-regulating medications. According to the United Nations Population Fund's June 2024 article 'Ageing', the worldwide share of people aged 65 years and older reached 10.3 percent in 2024, a figure that has nearly doubled since 1974. This demographic shift translates directly into higher prescription volumes, as evidenced by the NHS Business Services Authority reporting that Atorvastatin was the most dispensed chemical substance in England in 2024, with 65 million items provided during the 2023/2024 financial year.

Market Challenge

The primary challenge restricting the growth of the Global Statin Market is patient non-adherence and the discontinuation of therapy triggered by documented side effects, specifically muscle pain and increased blood sugar levels. When patients experience these adverse reactions, they frequently cease their medication or fail to follow prescribed regimens, a pattern that directly erodes market volume by terminating the long-term prescription cycles essential for the pharmaceutical sector's recurring revenue. Furthermore, the fear of these side effects creates a psychological barrier to initiating treatment, causing eligible patients to delay or refuse statin therapy despite the clinical necessity for lipid management.

This impediment creates a significant gap between the addressable patient population and the actual volume of treated individuals. Data from the European Society of Cardiology in 2024 highlighted that approximately 21.8 percent of patients at high or very high cardiovascular risk were not receiving any lipid-lowering treatment. This statistic underscores how intolerance and adherence issues effectively hamper market penetration, preventing the industry from fully capitalizing on the rising global demand for cardiovascular protection.

Market Trends

The increasing adoption of Fixed-Dose Combination (FDC) therapies, particularly those pairing statins with ezetimibe, enables aggressive lipid lowering without maximizing statin dosages. This strategy mitigates the side effects associated with high-dose monotherapy while delivering superior clinical outcomes. According to a meta-analysis reported by News-Medical.net in March 2025, combining ezetimibe with high-dose statins resulted in a significant 19 percent reduction in the risk of death from any cause compared to statins alone, prompting pharmaceutical companies to prioritize these dual-action formulations to meet the demand for effective cholesterol management.

Simultaneously, the emergence of cardiovascular polypills is transforming secondary prevention by consolidating statins, antihypertensives, and aspirin into single-dosage forms. This trend addresses patient non-adherence by simplifying complex daily regimens, offering substantial potential to reduce the global disease burden. As noted by tctmd.com in July 2025, the widespread adoption of such single-pill combination therapies could prevent up to 29 million deaths globally by 2050, leading manufacturers to increasingly invest in these multi-mechanism products to secure long-term revenue from the preventative care sector.

Key Market Players

  • Abbott Laboratories Ltd.
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Biocon Ltd.
  • Concord Biotech Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Statin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Statin Market, By Type

  • Synthetic statin
  • Natural statin

Statin Market, By End-user

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • others

Statin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Statin Market.

Available Customizations:

Global Statin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Statin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Synthetic statin, Natural statin)
    • 5.2.2. By End-user (Hospitals & Clinics, Ambulatory Surgical Centers, others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Statin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Statin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-user
    • 6.3.2. Canada Statin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-user
    • 6.3.3. Mexico Statin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-user

7. Europe Statin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Statin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-user
    • 7.3.2. France Statin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-user
    • 7.3.3. United Kingdom Statin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-user
    • 7.3.4. Italy Statin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-user
    • 7.3.5. Spain Statin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-user

8. Asia Pacific Statin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Statin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-user
    • 8.3.2. India Statin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-user
    • 8.3.3. Japan Statin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-user
    • 8.3.4. South Korea Statin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-user
    • 8.3.5. Australia Statin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-user

9. Middle East & Africa Statin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Statin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-user
    • 9.3.2. UAE Statin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-user
    • 9.3.3. South Africa Statin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-user

10. South America Statin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Statin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-user
    • 10.3.2. Colombia Statin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-user
    • 10.3.3. Argentina Statin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Statin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. AstraZeneca Plc
  • 15.4. Aurobindo Pharma Ltd.
  • 15.5. Biocon Ltd.
  • 15.6. Concord Biotech Ltd.
  • 15.7. Merck and Co. Inc.
  • 15.8. Novartis AG
  • 15.9. Pfizer Inc.
  • 15.10. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer